Pablo Anaya

Statistics

Publications

Citations

H-Index

Active since

2015

Affiliations

Pablo Anaya is an author at IQVIA (United States) specializing in cost-effectiveness analysis, cost-utility analysis, and cost-effectiveness modeling.

Publications per year

2015–2021

Publications

Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel

Óscar Arrieta, Pablo Anaya, Vicente Morales‐Oyarvide et al. · The European Journal of Health Economics · 2015 · 24 citations

Medicine, Oncology, Pharmacoeconomics +11

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia

Hélène Parisé, Robert Espinosa, Katherine Dea et al. · PharmacoEconomics - Open · 2019 · 12 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico

Fernando Carlos, Jorge A. Gómez, Pablo Anaya et al. · Human Vaccines & Immunotherapeutics · 2015 · 11 citations · Full text

Pharmacy, Infectious Diseases, Pediatrics +17

Mortality from cancer in Mexico: 2015 update

Fernando Aldaco-Sarvide, Perla Pérez-Pérez, María G. Cervantes-Sánchez et al. · Gaceta Mexicana de Oncología · 2019 · 11 citations · Full text

Medicine, Health Sciences, Oncology +16

Cost-effectiveness of a self-management and comprehensive training intervention in patients with type 2 diabetes up to 5 years of diagnosis in a specialized hospital in Mexico City

Sergio Hernández-Jiménez, Ana Cristina García-Ulloa, Pablo Anaya et al. · BMJ Open Diabetes Research & Care · 2021 · 10 citations · Full text

Pharmacy, Pharmacoeconomics, Cost-effectiveness Analysis +16

1–5 of 5